Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 49, Issue 5 (May 2011)

Issues

Laboratory assessment of new anticoagulants

Meyer M. Samama
  • Hôtel-Dieu University Hospital, Paris, France
  • Biomnis Laboratory, Ivry-sur-Seine, France
  • Email:
/ Céline Guinet
  • Biomnis Laboratory, Ivry-sur-Seine, France
Published Online: 2011-02-03 | DOI: https://doi.org/10.1515/CCLM.2011.134

Abstract

With the introduction of new anticoagulant agents, there is a need for information on which coagulation tests are most suitable. These agents react differently to assays used to monitor older anticoagulant agents because they have alternative modes of action. Therefore, other tests, or modifications of existing tests which are more appropriate for newer agents, are needed. The prothrombin time test (with conversion to the international normalized ratio) is usually used to monitor warfarin. However, conversion to the international normalized ratio is not appropriate for measuring the effects of fondaparinux, dabigatran, rivaroxaban or apixaban. Instead, chromogenic assays, one-step prothrombinase-induced clotting time test and the HepTest with reduced incubation time, are among the different or modified tests that appear to give the most reproducible and accurate results. The tests show variations in response to anticoagulants – some of which have clinical relevance. Thus, it is important to be aware of the observed variations in order to prevent the misinterpretation of test results.

Keywords: apixaban; argatroban; dabigatran; fondaparinux; rivaroxaban

About the article

Corresponding author: Meyer M. Samama, Scientific Director, 78 avenue de Verdun, BP 110, 94200 Ivry-sur-Seine Cedex, France Phone: +33 1 49 59 16 03, Fax: +33 1 49 59 15 29


Received: 2010-09-14

Accepted: 2010-12-06

Published Online: 2011-02-03

Published in Print: 2011-05-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2011.134.

Export Citation

©2011 by Walter de Gruyter Berlin New York. Copyright Clearance Center

Comments (0)

Please log in or register to comment.
Log in